ENANTHATE 250 (Testosterone Enanthate) is an esterified derivative of endogenous testosterone utilized in androgen replacement protocols for male patients with clinically diagnosed hypogonadism. It is indicated in conditions such as delayed sexual maturation, growth deficiencies linked to androgen insufficiency, and testicular dysfunction resulting from genetic anomalies, hypothalamic-pituitary axis disruption, or cytotoxic treatments like chemotherapy. Additionally, testosterone enanthate is employed as an adjuvant therapy in women diagnosed with specific forms of advanced-stage breast cancer. This formulation is delivered intramuscularly, containing 250mg of testosterone enanthate per milliliter, suspended in a sterile oil vehicle with pharmaceutical-grade excipients.
Metabolic Interactions
Testosterone enanthate acts as a slow-release prodrug of testosterone. Upon intramuscular administration, it undergoes enzymatic cleavage, releasing free testosterone which binds to intracellular androgen receptors. This binding initiates transcriptional activation of androgen-responsive genes involved in the development of male reproductive structures, spermatogenesis, and secondary sexual traits. The compound exhibits robust androgenic activity and moderate anabolic effects, including facilitation of muscle protein synthesis, enhanced nitrogen retention, increased bone mineral density, and skeletal maturation.
Dosage
The typical dosing regimen involves 250mg administered via deep intramuscular injection every 1 to 4 weeks, adjusted according to patient response and serum testosterone levels.
Drug Interactions
Patients should notify their healthcare provider if they are using any of the following agents prior to starting ENANTHATE 250, due to potential pharmacodynamic or pharmacokinetic interactions: